IND Enabling Study to prepare Silo Pharma Homing Peptides for Clinic ENGLEWOOD CLIFFS, N.J., March 31, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announces that it has entered into an agreement with Frontage Laboratories, a CRO (contract research organization)…


Previous articleAlbert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia
Next articleMydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update